Although typhoid vaccination is not generally recommended in the United States, because it is a low occurrence zone, it is recommended for travelers who will have prolonged exposure to potentially contaminated food and water in smaller cities or villages, as well as rural areas of the world, where typhoid has been identified as a problem. Typhim Vi TM is the newest injectable vaccine on the market, and its safety has been assessed in more than ten thousand subjects in clinical trials in countries of high and low occurrence. A single injection of 0.5 ml is given at least two weeks prior to expected exposure to Salmonella typhi. Re-immunization is recommended every two years under conditions of repeated or continuous exposure to the Salmonella typhi organism. It is also contraindicated in patients with a history of hypersensitivity to any component of the vaccine.
Side effects can be very serious.
Seek immediate medical attention if any of the following occur, involving the . . . . . This sequence should be completed at least one week prior to potential exposure to the Salmonella typhi. The optimum booster schedule has not been determined, but efficacy has been shown to persist for at least five years. The Food and Drug Administration recommends a booster dose every four years, if exposure to typhoid is continuous or repeated. This vaccine is a parenteral inactivated series of shots.